BioNTech (NASDAQ:BNTX) and OncoC4 have had a partial clinical hold placed by the FDA on a Phase 3 study for their drug ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

BioNTech (NASDAQ:BNTX) shares fell Friday after the company said it had been informed by partner OncoC4 that FDA placed ...

The new biotech will operate under OncoC4’s name and will continue to be led by CEO Liu. Specific financials of the deal were not disclosed. BioNTech's cancer push continues, coughing up $200M ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

In March 2023, OncoC4 announced a strategic collaboration with BioNTech to co-develop and commercialize ONC-392 in multiple solid tumor indications. OncoC4 received $200M upfront and is eligible ...

OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. BioNTech Forward-looking Statements This press release contains forward-looking statements within the meaning of ...

LONDON (Reuters) -Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer and BioNTech had filed their ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price target of $145.00. The company’s shares closed last ...

BioNTech is the Marketing Authorization Holder ... Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.